Fidia Pharma has acquired Altacor, a specialist ophthalmology company, for an undisclosed amount. This corporate acquisition sees Fidia Pharma buying Altacor's entire portfolio and operations, integrating its established market presence and specialized product lines.
Altacor is an ophthalmic specialty pharmaceutical company that markets a portfolio of products in the fields of ocular surface disease and ophthalmic surgery. It differentiates its development products primarily through formulation or reprofiling existing compounds. Altacor currently commercializes products such as the Clinitas range for dry eye conditions and BioLon, a high-quality viscoelastic for cataract surgery, in the UK and Ireland through its own sales and marketing organization and network. The company has also been actively pursuing European expansion.
This acquisition is strategically significant for Fidia Pharma, as it substantially strengthens its footprint and product offering within the ophthalmology sector. It provides Fidia Pharma with an immediate, established presence in the UK and Irish markets and adds a specialized portfolio of ocular surface disease and surgical products. The integration of Altacor’s Clinitas dry eye solutions and BioLon surgical viscoelastic complements Fidia Pharma’s existing therapeutic areas and expands its reach to healthcare professionals and patients.
Expected synergies from this acquisition include enhanced market penetration for Altacor’s products through Fidia Pharma’s broader distribution capabilities and resources. Fidia Pharma gains Altacor's specialized expertise in ophthalmic product development and its established commercial infrastructure. The combination aims to leverage these strengths to optimize product development and market access.
The combined entity is anticipated to hold a more robust position in the European ophthalmology market, offering an expanded and comprehensive suite of products to address various eye conditions. This strategic move is expected to accelerate growth and innovation in the field, ultimately aiming to deliver broader and more specialized ophthalmic solutions to patient care.